Haleon (NYSE: HLN) shares Q1 2026 trading update and investor call info
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Haleon plc has made its Q1 2026 trading statement for the year ending 31 December 2026 available online. The full document can be accessed via a linked PDF and on the company’s investor relations website, and has also been submitted to the UK regulator’s National Storage Mechanism.
The company will host a short presentation and Q&A for analysts and shareholders at 9:00am BST on 29 April 2026, led by the Chief Executive Officer and Chief Financial Officer, with dial-in details provided for UK, US and other participants. An archived webcast of the Q&A will be available later the same day.
Positive
- None.
Negative
- None.
Key Figures
Trading statement period: Q1 2026
Financial year end: 31 December 2026
Results presentation time: 9:00am BST
+1 more
4 metrics
Trading statement period
Q1 2026
Quarterly trading statement period referenced in the report
Financial year end
31 December 2026
Year ending date for which Q1 trading statement is issued
Results presentation time
9:00am BST
Start time of analyst and shareholder presentation on 29 April 2026
Q&A passcode
975813
Passcode for the analyst and shareholder Q&A call
Key Terms
foreign private issuer, trading statement, National Storage Mechanism, Q&A
4 terms
foreign private issuer regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
trading statement financial
"Haleon plc: 2026 Q1 Trading Statement 29 April 2026"
National Storage Mechanism regulatory
"submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism"
A national storage mechanism is an official, centralized electronic repository where companies and regulators file and keep required corporate documents such as prospectuses, financial statements and regulatory disclosures. For investors it is the authoritative public source to find and verify key papers — like using a government-run public archive or filing cabinet — so you can check the original documents for due diligence, compliance and to confirm claims made in news or marketing.
Q&A financial
"A short presentation followed by Q&A will be hosted by Brian McNamara"
Q&A is a live or recorded session in which company leaders or spokespeople answer questions from investors, analysts, or journalists following presentations, earnings calls, or announcements. It matters to investors because the answers reveal management’s priorities, clarify numbers or plans, expose risks or opportunities, and often change market perceptions—similar to asking follow-up questions to judge how confident and consistent someone really is.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April
2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
29
April 2026 - “Haleon 2026 Q1 Trading
Statement”
|
|
99.2
|
29
April 2026 - “Haleon
2026 Q1 Trading Statement”
|
99.1
Haleon plc: 2026 Q1 Trading Statement
29 April 2026: Haleon plc
(the "Company" or "Haleon") today announces its Q1
trading statement for the year ending 31 December 2026 is available
at:
http://www.rns-pdf.londonstockexchange.com/rns/2888C_1-2026-4-28.pdf .
The Q1 trading statement will also be available on the Haleon
website www.haleon.com/investors,
and has been submitted in full unedited text to the Financial
Conduct Authority's National Storage Mechanism and will shortly be
available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Presentation for analysts and shareholders
A short presentation followed by Q&A will be hosted by Brian
McNamara, Chief Executive Officer, and Dawn Allen, Chief Financial
Officer at 9:00am BST (10:00am CEST) on 29 April 2026, which can be
accessed at www.haleon.com/investors/.
For analysts and shareholders wishing to ask questions on the
Q&A call, please use the dial-in details below which will have
a Q&A facility:
|
UK:
|
+44 (0) 808 189
0158
|
|
US:
|
+1 855 979 6654
|
|
All other:
|
+44 (0) 203 936 2999
|
|
Passcode:
|
975813
|
An archived webcast of the Q&A call will be available later on
the day of the results and can be accessed
at www.haleon.com/investors.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
||
|
Jo Russell
|
+44 7787 392441
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Victoria Durman
|
+44 7894 505730
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused
on better everyday health. Our people, our brands, our research,
our investment and our innovation are aimed at improving the
everyday health of consumers. Our product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Our superior brands - such
as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion
consumers and are recommended by health professionals around the
world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
April 29, 2026
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
FAQ
What does Haleon (HLN) announce in its April 2026 Form 6-K?
Haleon announces that its Q1 2026 trading statement for the year ending 31 December 2026 is now available online and via the UK National Storage Mechanism. Investors can access the full text through links on Haleon’s dedicated investor relations website.
Where can investors access Haleon’s Q1 2026 trading statement?
Investors can access the Q1 2026 trading statement via a linked PDF hosted by the London Stock Exchange and on Haleon’s investor relations page at www.haleon.com/investors. It is also available through the Financial Conduct Authority’s National Storage Mechanism portal.
How can investors join the Haleon Q1 2026 Q&A call by phone?
Investors can join by dialing +44 (0) 808 189 0158 in the UK, +1 855 979 6654 in the US, or +44 (0) 203 936 2999 from other locations, using passcode 975813. These numbers provide access to the Q&A facility described in the announcement.
Will a replay or archived webcast be available for Haleon’s Q1 2026 call?
Yes. An archived webcast of the Q&A call will be available later on the day of the results. It can be accessed via Haleon’s investor relations website, allowing those who cannot attend live to review the management discussion.
Who are the key contacts for Haleon (HLN) investor and media enquiries?
Investor contacts include Jo Russell and Rakesh Patel, while media contacts include Zoë Bird and Victoria Durman. The filing lists UK mobile numbers and dedicated email addresses for investor-relations@haleon.com and corporate.media@haleon.com to handle enquiries.